Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00495339
Recruitment Status : Completed
First Posted : July 3, 2007
Last Update Posted : March 4, 2009
Information provided by:

Brief Summary:

Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB.

Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.

Condition or disease Intervention/treatment Phase
Tuberculosis, Pulmonary Drug: Levofloxacin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)
Study Start Date : June 2007
Actual Primary Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: 1
Drug: Levofloxacin
500-1000 mg once a day daily per os with combination of drugs.

Primary Outcome Measures :
  1. Number of patients with bacterioexcretion [ Time Frame: 1 month, 2 months, 3 months ]
  2. Dynamics of chest radiograph [ Time Frame: 3 months ]
  3. Dynamics of Intoxication [ Time Frame: 1 month, 2 months, 3 months ]
  4. All clinical and laboratory adverse events [ Time Frame: from the signature of the Informed Concent Form (ICF) up to the end of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Drug-resistant pulmonary tuberculosis laboratory diagnosed

Exclusion Criteria:

  • Known hypersensitivity to levofloxacin, other quinolones
  • Patient with epilepsy and central nervous system diseases
  • Renal insufficiency with serum creatinine lower than 50 ml/min
  • Arterial hypertension, ischemic heart disease in acute phase
  • Gastro-intestinal diseases, liver diseases in acute phase
  • History of drug and alcohol abuse
  • Patient with history of tendon disorders related to fluoroquinolone administration
  • Pregnancy and breast-feeding women
  • Immune system disorders related to chemotherapy, AIDS, long term administration of corticosteroids

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00495339

Layout table for location information
Russian Federation
Moscow, Russian Federation
Sponsors and Collaborators
Layout table for investigator information
Study Director: Marina Atarshchikova Sanofi

Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00495339    
Other Study ID Numbers: LEVOF_L_00972
First Posted: July 3, 2007    Key Record Dates
Last Update Posted: March 4, 2009
Last Verified: June 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors